Emerging role of GLP-1 receptor agonists in the treatment of obesity

Lisa M Neff1, Robert F Kushner21Division of Endocrinology, Metabolism, and Molecular Medicine, 2Division of General Medicine, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, USAAbstract: The prevalence of obesity has increased dramatically in recent decades,...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autor principal:	Neff LM
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2010
Materias:	obesity GLP-1 exenatide liraglutide Specialties of internal medicine RC581-951
Acceso en línea:	https://doaj.org/article/c3a463ab4c97492ba35bd936794ad4f1
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:c3a463ab4c97492ba35bd936794ad4f1
record_format	dspace
spelling	oai:doaj.org-article:c3a463ab4c97492ba35bd936794ad4f12021-12-02T02:16:23ZEmerging role of GLP-1 receptor agonists in the treatment of obesity1178-7007https://doaj.org/article/c3a463ab4c97492ba35bd936794ad4f12010-07-01T00:00:00Zhttps://www.dovepress.com/emerging-role-of-glp-1-receptor-agonists-in-the-treatment-of-obesity-peer-reviewed-article-DMSOhttps://doaj.org/toc/1178-7007Lisa M Neff1, Robert F Kushner21Division of Endocrinology, Metabolism, and Molecular Medicine, 2Division of General Medicine, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, USAAbstract: The prevalence of obesity has increased dramatically in recent decades, both in the US and worldwide. Pharmacotherapy can augment the weight-reducing effects of lifestyle modification and can facilitate long-term weight maintenance. However, there is a paucity of pharmacologic agents approved for the treatment of obesity, and the use of existing weight loss medications is frequently limited by contraindications, drug interactions, adverse effects, limited coverage by third-party payers, and cost. In recent years, there has been an increased understanding and appreciation of the role of gastrointestinal hormones in the control of body weight. One such hormone, GLP-1, also plays an important role in glucose homeostasis. GLP-1 receptor agonists, such as exenatide and liraglutide, have been developed and are already approved for the treatment of type 2 diabetes. There has also been interest in the use of GLP-1 receptor agonists for the treatment of obesity in nondiabetic patients. This review explores the potential utility and limitations of exenatide and liraglutide as therapeutic agents for obesity.Keywords: obesity, GLP-1, exenatide, liraglutideNeff LMDove Medical PressarticleobesityGLP-1exenatideliraglutideSpecialties of internal medicineRC581-951ENDiabetes, Metabolic Syndrome and Obesity: Targets and Therapy, Vol Volume 3, Pp 263-273 (2010)
institution	DOAJ
collection	DOAJ
language	EN
topic	obesity GLP-1 exenatide liraglutide Specialties of internal medicine RC581-951
spellingShingle	obesity GLP-1 exenatide liraglutide Specialties of internal medicine RC581-951 Neff LM Emerging role of GLP-1 receptor agonists in the treatment of obesity
description	Lisa M Neff1, Robert F Kushner21Division of Endocrinology, Metabolism, and Molecular Medicine, 2Division of General Medicine, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, USAAbstract: The prevalence of obesity has increased dramatically in recent decades, both in the US and worldwide. Pharmacotherapy can augment the weight-reducing effects of lifestyle modification and can facilitate long-term weight maintenance. However, there is a paucity of pharmacologic agents approved for the treatment of obesity, and the use of existing weight loss medications is frequently limited by contraindications, drug interactions, adverse effects, limited coverage by third-party payers, and cost. In recent years, there has been an increased understanding and appreciation of the role of gastrointestinal hormones in the control of body weight. One such hormone, GLP-1, also plays an important role in glucose homeostasis. GLP-1 receptor agonists, such as exenatide and liraglutide, have been developed and are already approved for the treatment of type 2 diabetes. There has also been interest in the use of GLP-1 receptor agonists for the treatment of obesity in nondiabetic patients. This review explores the potential utility and limitations of exenatide and liraglutide as therapeutic agents for obesity.Keywords: obesity, GLP-1, exenatide, liraglutide
format	article
author	Neff LM
author_facet	Neff LM
author_sort	Neff LM
title	Emerging role of GLP-1 receptor agonists in the treatment of obesity
title_short	Emerging role of GLP-1 receptor agonists in the treatment of obesity
title_full	Emerging role of GLP-1 receptor agonists in the treatment of obesity
title_fullStr	Emerging role of GLP-1 receptor agonists in the treatment of obesity
title_full_unstemmed	Emerging role of GLP-1 receptor agonists in the treatment of obesity
title_sort	emerging role of glp-1 receptor agonists in the treatment of obesity
publisher	Dove Medical Press
publishDate	2010
url	https://doaj.org/article/c3a463ab4c97492ba35bd936794ad4f1
work_keys_str_mv	AT nefflm emergingroleofglp1receptoragonistsinthetreatmentofobesity
_version_	1718402618673332224

Emerging role of GLP-1 receptor agonists in the treatment of obesity

Ejemplares similares